Sökning: onr:"swepub:oai:DiVA.org:uu-510349" >
Real-world assessme...
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination : a one-year follow-up of the prospective clinical trial COVAXID
-
- Chen, Puran (författare)
- Karolinska Inst, Ctr Infect Med, Dept Med Huddinge, Stockholm, Sweden.
-
- Bergman, Peter (författare)
- Karolinska Institutet,Karolinska Univ Hosp, Dept Infect Dis, Stockholm, Sweden.;Karolinska Inst, Dept Lab Med, Clin Immunol, Stockholm, Sweden.
-
- Blennow, Ola (författare)
- Karolinska Univ Hosp, Dept Infect Dis, Stockholm, Sweden.;Karolinska Univ Hosp, Dept Transplantat, Stockholm, Sweden.;Karolinska Inst, Dept Clin Sci Intervent & Technol, Stockholm, Sweden.
-
visa fler...
-
- Hansson, Lotta (författare)
- Karolinska Institutet,Karolinska Univ Hosp, Dept Hematol, Stockholm, Sweden.;Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden.
-
- Mielke, Stephan (författare)
- Karolinska Institutet,Karolinska Univ Hosp Huddinge, Karolinska Comprehens Canc Ctr, Dept Cellular Therapy & Allogene Stem Cell Transpl, Stockholm, Sweden.;Karolinska Inst, Dept Lab Med Biomol & Cellular Med, Stockholm, Sweden.
-
- Nowak, Piotr (författare)
- Karolinska Univ Hosp, Dept Infect Dis, Stockholm, Sweden.;Karolinska Inst, Dept Med Huddinge, Infect Dis, Stockholm, Sweden.
-
- Söderdahl, Gunnar (författare)
- Karolinska Univ Hosp, Dept Transplantat, Stockholm, Sweden.;Karolinska Inst, Dept Clin Sci Intervent & Technol, Stockholm, Sweden.
-
- Österborg, Anders (författare)
- Karolinska Univ Hosp, Dept Hematol, Stockholm, Sweden.;Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden.
-
- Smith, C. I. Edvard (författare)
- Karolinska Institutet,Karolinska Univ Hosp, Dept Infect Dis, Stockholm, Sweden.;Karolinska Inst, Dept Lab Med Biomol & Cellular Med, Stockholm, Sweden.
-
- Vesterbacka, Jan (författare)
- Karolinska Univ Hosp, Dept Infect Dis, Stockholm, Sweden.;Karolinska Inst, Dept Med Huddinge, Infect Dis, Stockholm, Sweden.
-
- Wullimann, David (författare)
- Karolinska Inst, Ctr Infect Med, Dept Med Huddinge, Stockholm, Sweden.
-
- Cuapio, Angelica (författare)
- Karolinska Inst, Ctr Infect Med, Dept Med Huddinge, Stockholm, Sweden.
-
- Akber, Mira (författare)
- Karolinska Inst, Ctr Infect Med, Dept Med Huddinge, Stockholm, Sweden.
-
- Bogdanovic, Gordana (författare)
- Karolinska Univ Hosp, Dept Clin Microbiol, Stockholm, Sweden.;Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden.
-
- Muschiol, Sandra (författare)
- Karolinska Univ Hosp, Dept Clin Microbiol, Stockholm, Sweden.;Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden.
-
- Åberg, Mikael (författare)
- Uppsala universitet,Science for Life Laboratory, SciLifeLab,Klinisk kemi
-
- Lore, Karin (författare)
- Karolinska Inst, Dept Med Solna, Stockholm, Sweden.
-
- Chen, Margaret Sällberg (författare)
- Karolinska Inst, Dept Dent Med, Stockholm, Sweden.
-
- Buggert, Marcus (författare)
- Karolinska Institutet,Karolinska Inst, Ctr Infect Med, Dept Med Huddinge, Stockholm, Sweden.
-
- Ljungman, Per (författare)
- Karolinska Univ Hosp Huddinge, Karolinska Comprehens Canc Ctr, Dept Cellular Therapy & Allogene Stem Cell Transpl, Stockholm, Sweden.;Karolinska Inst, Dept Med Huddinge, Div Hematol, Stockholm, Sweden.
-
- Aleman, Soo (författare)
- Karolinska Institutet,Karolinska Univ Hosp, Dept Infect Dis, Stockholm, Sweden.;Karolinska Inst, Dept Med Huddinge, Infect Dis, Stockholm, Sweden.;Karolinska Univ Hosp, Dept Infect Dis, S-14157 Stockholm, Sweden.
-
- Ljunggren, Hans-Gustaf (författare)
- Karolinska Inst, Ctr Infect Med, Dept Med Huddinge, S-14152 Stockholm, Sweden.
-
visa färre...
-
Karolinska Institutet Karolinska Inst, Ctr Infect Med, Dept Med Huddinge, Stockholm, Sweden (creator_code:org_t)
- Elsevier, 2023
- 2023
- Engelska.
-
Ingår i: EBioMedicine. - : Elsevier. - 2352-3964. ; 94
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Immunocompromised patients have varying responses to SARS-CoV-2 mRNA vaccination. However, there is limited information available from prospective clinical trial cohorts with respect to long-term immunogenicity-related responses in these patient groups following three or four vaccine doses, and in applicable cases infection.Methods: In a real-world setting, we assessed the long-term immunogenicity-related responses in patients with primary and secondary immunodeficiencies from the prospective open-label clinical trial COVAXID. The original clinical trial protocol included two vaccine doses given on days 0 and 21, with antibody titres measured at six different timepoints over six months. The study cohort has subsequently been followed for one year with antibody responses evaluated in relation to the third and fourth vaccine dose, and in applicable cases SARS-CoV-2 infection. In total 356/539 patients were included in the extended cohort. Blood samples were analysed for binding antibody titres and neutralisation against the Spike protein for all SARS-CoV-2 variants prevailing during the study period, including Omicron subvariants. SARS-CoV-2 infections that did not require hospital care were recorded through quarterly in-person, or phone-, interviews and assessment of IgG antibody titres against SARSCoV-2 Nucleocapsid. The original clinical trial was registered in EudraCT (2021-000175-37) and clinicaltrials.gov (NCT04780659).Findings: The third vaccine dose significantly increased Spike IgG titres against all the SARS-CoV-2 variants analysed in all immunocompromised patient groups. Similarly, neutralisation also increased against all variants studied, except for Omicron. Omicron-specific neutralisation, however, increased after a fourth dose as well as after three doses and infection in many of the patient subgroups. Noteworthy, however, while many patient groups mounted strong serological responses after three and four vaccine doses, comparably weak responders were found among patient subgroups with specific primary immunodeficiencies and subgroups with immunosuppressive medication.Interpretation: The study identifies particularly affected patient groups in terms of development of long-term immunity among a larger group of immunocompromised patients. In particular, the results highlight poor vaccine-elicited neutralising responses towards Omicron subvariants in specific subgroups. The results provide additional knowledge of relevance for future vaccination strategies.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Infektionsmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Infectious Medicine (hsv//eng)
Nyckelord
- SARS-CoV-2
- COVID-19
- mRNA vaccine
- Clinical study
- Primary immunodeficiency disease
- HIV
- Solid organ transplantation
- Haematopoietic stem cell transplantation
- Chronic lymphocytic leukemia
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Chen, Puran
-
Bergman, Peter
-
Blennow, Ola
-
Hansson, Lotta
-
Mielke, Stephan
-
Nowak, Piotr
-
visa fler...
-
Söderdahl, Gunna ...
-
Österborg, Ander ...
-
Smith, C. I. Edv ...
-
Vesterbacka, Jan
-
Wullimann, David
-
Cuapio, Angelica
-
Akber, Mira
-
Bogdanovic, Gord ...
-
Muschiol, Sandra
-
Åberg, Mikael
-
Lore, Karin
-
Chen, Margaret S ...
-
Buggert, Marcus
-
Ljungman, Per
-
Aleman, Soo
-
Ljunggren, Hans- ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Infektionsmedici ...
- Artiklar i publikationen
-
EBioMedicine
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet